ZHONGSHENGYAOYE(SZ:002317) GLP1减重宝典·2025-12-04 04:10Core Viewpoint - The article discusses the recent developments in GLP-1/GIP dual receptor agonist RAY1225, highlighting its clinical research approval for treating metabolic-associated fatty liver disease (MASH) and its potential in weight management and diabetes treatment [5][6]. Group 1: Product Development - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has received implied approval for RAY1225, a long-acting GLP-1/GIP dual receptor agonist, for clinical research in MASH [5]. - RAY1225 is an innovative polypeptide drug developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., which has previously obtained clinical research approval for indications related to type 2 diabetes and overweight/obesity [5]. Group 2: Clinical Trials - The company announced results from the Phase II clinical trial (REBUILDING-1) for weight management, which included 172 participants who were either overweight or obese [6]. - Participants received RAY1225 (3 mg, 6 mg, 9 mg) or a placebo, with injections administered every two weeks over a 24-week treatment period [6]. - The dosing regimen included a gradual titration to target doses, with total administered doses of 30 mg for the 3 mg group, 50 mg for the 6 mg group, and 68 mg for the 9 mg group [6].